Portage Commences Trading on Nasdaq
Trading of ordinary shares begins under the symbol “PRTG” Portage Biotech Inc. a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today announced the commencement of trading of its ordinary shares on the NASDAQ Capital Market under the symbol “PRTG.” The Company’s ordinary shares will continue to trade on the Canadian Securities Exchange .As one of the …
Trading of ordinary shares begins under the symbol “PRTG”
Portage Biotech Inc. (CSE: PBT.U) (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today announced the commencement of trading of its ordinary shares on the NASDAQ Capital Market (“Nasdaq”) under the symbol “PRTG.” The Company’s ordinary shares will continue to trade on the Canadian Securities Exchange (CSE).
Portage BioTech Inc : Portage Commences Trading on Nasdaq finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that Erez Raphael, Chief Executive.
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
USA - English
Company, with its Commercialization Partner, Chiesi, poised to commercialize PRX-102
Additional data and milestones expected throughout 2021
News provided by
Share this article
Share this article
CARMIEL, Israel, Feb. 18, 2021 /PRNewswire/ Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx
® plant cell–based protein expression system, today announced it has completed a raise bringing in gross proceeds of approximately $40 million, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer & Co. acting as co-manager.